- Home
- IOVA vs HASI Comparison
IOVA vs HASI Comparison
Compare IOVA & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- HASI
- Stock Information
- Founded
- IOVA 2007
- HASI 1981
- Country
- IOVA United States
- HASI United States
- Employees
- IOVA N/A
- HASI N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- HASI Real Estate Investment Trusts
- Sector
- IOVA Health Care
- HASI Real Estate
- Exchange
- IOVA Nasdaq
- HASI Nasdaq
- Market Cap
- IOVA 1.0B
- HASI N/A
- IPO Year
- IOVA N/A
- HASI 2013
- Fundamental
- Price
- IOVA $1.73
- HASI $26.63
- Analyst Decision
- IOVA Strong Buy
- HASI Strong Buy
- Analyst Count
- IOVA 9
- HASI 11
- Target Price
- IOVA $18.22
- HASI $39.36
- AVG Volume (30 Days)
- IOVA 9.3M
- HASI 1.1M
- Earning Date
- IOVA 05-08-2025
- HASI 05-07-2025
- Dividend Yield
- IOVA N/A
- HASI 6.49%
- EPS Growth
- IOVA N/A
- HASI N/A
- EPS
- IOVA N/A
- HASI 1.08
- Revenue
- IOVA $164,070,000.00
- HASI $126,702,000.00
- Revenue This Year
- IOVA $182.20
- HASI $195.06
- Revenue Next Year
- IOVA $62.10
- HASI $11.34
- P/E Ratio
- IOVA N/A
- HASI $23.86
- Revenue Growth
- IOVA 13698.99
- HASI N/A
- 52 Week Low
- IOVA $2.70
- HASI $21.98
- 52 Week High
- IOVA $13.60
- HASI $36.56
- Technical
- Relative Strength Index (RSI)
- IOVA 24.56
- HASI 55.47
- Support Level
- IOVA $3.02
- HASI $25.05
- Resistance Level
- IOVA $3.31
- HASI $26.97
- Average True Range (ATR)
- IOVA 0.24
- HASI 0.75
- MACD
- IOVA -0.08
- HASI 0.31
- Stochastic Oscillator
- IOVA 6.00
- HASI 80.40
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.